Narcolepsy and Pandemic Influenza Vaccination
What we know and what we need to know before the next Pandemic

 March 26-27, 2018
Eurostation II, Place Victor Horta
Brussels, Belgium

In partnership with
Federal Agency for Medicines and Health Products (FAMHP)
Vaccine Center of Excellence

This meeting will be held under Chatham House Rule

 

Influenza Pandemics occur when an influenza strain circulates that humans have not been exposed to before. This may lead to widespread circulation and a high case fatality rate.

In 2009 pandemic, several H1N1 vaccines were developed against the new H1N1 virus and were extensively used. In Finland and Sweden an increase in narcolepsy was noted after the mass vaccination with one of these vaccines.  Disparate results were seen in other countries with other vaccines.  In addition, an increase of narcolepsy has been reported in countries in Asia following wild type influenza infection.

The goal of this meeting is to be prepared for the next pandemic:

  • What are the latest data on the risk of narcolepsy following exposure to 2009 pandemic vaccines?
  • What scientific data are available and what data are lacking to explain the phenomena that was seen in 2009-10?
  • What additional work is needed to prepare for potential use of adjuvanted vaccines for a future pandemic ?  

 View the Agenda   

Autogenous Vaccines and Their Role
in Animal Health Strategy

September 25-26, 2017
Venue: Het Pand, University of Ghent

Co-organized by IABS-EU and University of Ghent / PROVAXS

 

 

 The purpose of this conference is to start from an overview on the current situation and needs from the perspective of regulators, scientists, manufacturers and the end-user (veterinarians). The main focus will be on food producing animals, including fish. Further, proposals will be presented for a harmonized approach which will lead to a better understanding of the rational for the intended use, better knowledge on the nature of isolates and improved production and quality of the final products. In addition, advanced techniques and methods will be presented and discussed to identify and propagate isolates, to upgrade production and to quickly estimate safety and even efficacy of autogenous vaccines by in vitro methods.

Recommendations will be drafted on how to improve the EU-legislation and communication between the EU-Member States on autogenous vaccines and on ways to increase transparency on quality and safety of the vaccines.

 

International Alliance for Biological Standardization


Twitter Feed

IABS Diagnostics in the Veterinary Field. May 15-17. Wiesbaden. Topic: Isothermal amplification methods for the det… https://t.co/88iCFE42Ir
IABS Diagnostics in the Veterinary Field. May 15-17, Wiesbaden. Topic: Multiparameter-testing for pathogens and ant… https://t.co/k0w5FlwJdj
Follow IABS_global on Twitter

Contact Info

IABS, Rue de la Vallée, 3
CH-1204 Geneva

Switzerland
+ 41 22 301 10 36
+ 41 22 301 10 37
This email address is being protected from spambots. You need JavaScript enabled to view it.